Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology.
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular techniques, such as NanoString nCounter, have...
| Publicado en: | BMC Pulmonary Medicine Vol. 17; pp. 1 - 9 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
BioMed Central
5/26/2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123289914&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 123289914 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14712466 1CIL jtl: BMC Pulmonary Medicine issn: 14712466 maglogo: N pubinfo: dt: 5/26/2017 vid: 17 pid: 24147 pub: BioMed Central artinfo: ui: 123289914 123289914 NLM28549458 123289914 10.1186/s12890-017-0428-0 NLM28549458 123289914 ppf: 1 ppct: 8 formats: tig: atl: Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology. aug: au: Evangelista, Adriane F. Zanon, Maicon F. Carloni, Adriana Cruvinel de Paula, Flávia E. Morini, Mariana Andozia Ferreira-Neto, Maressa Soares, Iberê Cauduro Miziara, Jose Elias de Marchi, Pedro Scapulatempo-Neto, Cristovam Reis, Rui M. affil: Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos CEP 14784-400, São Paulo, Brazil sug: subj: Proteins Adenocarcinoma Lung Neoplasms RNA Analysis Retrospective Design RNA In Situ Hybridization, Fluorescence Immunohistochemistry Human ab: Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular techniques, such as NanoString nCounter, have been developed to detect ALK fusions with more accuracy and sensitivity.Methods: In the present study, we intended to validate a NanoString nCounter ALK-fusion panel in routine biopsies of FFPE lung cancer patients. A total of 43 samples were analyzed, 13 ALK-positive and 30 ALK-negative, as previously detected by FISH and/or immunohistochemistry.Results: The NanoString panel detected the presence of the EML4-ALK, KIF5B-ALK and TFG-ALK fusion variants. We observed that all the 13 ALK-positive cases exhibited genetic aberrations by the NanoString methodology. Namely, six cases (46.15%) presented EML-ALK variant 1, two (15.38%) presented EML-ALK variant 2, two (15.38%) presented EML-ALK variant 3a, and three (23.07%) exhibited no variant but presented unbalanced expression between 5'/3' exons, similar to other positive samples. Importantly, for all these analyses, the initial input of RNA was 100 ng, and some cases displayed poor RNA quality measurements.Conclusions: In this study, we reported the great utility of NanoString technology in the assessment of ALK fusions in routine lung biopsies of FFPE specimens. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|